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Key Points




POD,24 months was
associated with
inferior survival among
patients with MCL
after both intensive
and less intensive
frontline treatment.
Patients with POD,6
months or progressive
disease after frontline
treatment had the
highest risk of early
mortality.

Although an expanding array of effective treatments has resulted in recent improvement in
survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and
identiﬁcation of prognostic factors remains a priority. We assessed the prognostic impact of
time to progression of disease (POD) after ﬁrst-line therapy among 455 patients with relapsed
MCL. Patients were categorized by duration of ﬁrst remission as PRF/POD6, deﬁned as progressive disease during induction or POD within 6 months of diagnosis (n 5 65; 14%); POD6-24,
deﬁned as POD between 6 and 24 months after diagnosis (n 5 153; 34%); and POD.24, deﬁned
asPOD .24 months after diagnosis (n 5 237; 53%). The median overall survival fromPOD (OS2)
was 1.3 years (95% conﬁdence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95%
CI, 2-6.8) for those with POD6-24, and 8 years (95% CI, 6.2-NR) for those with POD.24. Median
OS2 was inferior in patients with early POD (deﬁned as PRF/POD6 or POD6-24) after both
intensive and less intensive frontline treatment. The prognostic performance of time until
POD was replicated in an independent cohort of 245 patients with relapsed MCL, with median
OS2 of 0.3 years (95% CI, 0.1-0.5) for PRF/POD6, 0.8 years (95% CI, 0.6-0.9) for POD6-24, and 2.4
years (95% CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with
relapsed MCL, identifying a high-risk population for future prospective studies.

Introduction
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma (NHL), representing ,10%
of all cases, with an increasing incidence in recent decades.1 Outcomes of patients with MCL have improved
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Among both indolent and aggressive NHL subtypes, time to progression of disease (POD) after frontline treatment is a robust prognostic
factor among patients with relapsed disease. In indolent NHL, including the follicular lymphoma and indolent nonfollicular lymphoma subtypes, POD within 24 months of frontline CIT (early POD) predicts
inferior overall survival (OS), suggesting that a subgroup of patients
with these diseases are predisposed to treatment resistance.17-20
Similarly, among patients with relapsed diffuse large B-cell lymphoma,
a short time to relapse predicts inferior survival.21-23 In MCL, relapse
within 12 months of autologous stem cell transplant (ASCT) has
been associated with inferior survival in a report including patients
who receive ASCT, either as frontline consolidation or after salvage
therapy.24 More recently, POD within 24 months of intensive
cytarabine-containing frontline therapy was associated with increased
mortality in comparison with later POD in a retrospective cohort of
patients with and a smaller prospective validation cohort.25
The prognostic signiﬁcance of early POD after less intensive frontline
therapies for MCL has not been evaluated, and given that the median
age at MCL diagnosis is 68 years, less intensive frontline treatment is
commonly used in clinical practice. We evaluated the prognostic signiﬁcance of time to POD in a large multiinstitutional MCL cohort
including patients treated with either intensive or less intensive frontline therapy and describe outcomes after classiﬁcation of secondline therapies among patients with primary refractory disease.

Methods
Patient selection
For our training cohort, patients aged $18 years with a diagnosis of
MCL treated from 2000 through 2017 were identiﬁed from 12 participating US medical centers. Clinical, pathologic, treatment, and outcome data were collected retrospectively. Institutional review board
approval was obtained at each participating center before data collection. Patients with documented POD at any time after frontline therapy
were included in the primary analysis. The study was conducted in
accordance with the Declaration of Helsinki.
MIPI risk score at diagnosis was calculated for patients with available
baseline lactate dehydrogenase level, Eastern Cooperative Oncology
Group (ECOG) performance status, and white blood cell count, as
previously described.10 The proliferation index, measured by immunostaining for Ki67 performed according to institutional standards,
was recorded, and patients were dichotomized according to the previously validated Ki67 cutoff of 30%.14,26,27 Cytogenetic analysis by
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conventional metaphase karyotyping, when available, was reviewed
retrospectively, and patients with $3 unrelated cytogenetic abnormalities, excluding t(11;14), were deﬁned as having CK.
Disease progression and treatment response were assessed by
investigators using available imaging studies according to response
criteria relevant to the era of treatment. Patients with documented
relapse of disease after frontline treatment were included in this analysis and were categorized into 3 groups: (1) refractory disease
deﬁned as progressive disease as best response to frontline therapy
or POD within 6 months of date of diagnosis (PRF/POD6), (2) POD
between 6 and 24 months of date of diagnosis, (POD6-24), and (3)
POD .24 months from date of diagnosis, (POD.24). A 6-month
POD cutoff was chosen to deﬁne the PRF/POD6 cohort, as that cutoff has been used to deﬁne refractory patients with transient response
to antilymphoma therapy28 and, in other NHL subtypes, has been
associated with the highest risk of early mortality.29 We deﬁned
relapse groups in the training cohort from date of diagnosis to date
of relapse, to account for a subset of patients with missing data for
date of initiation of frontline therapy. Intensive treatment was deﬁned
as receipt of high-dose cytarabine-containing induction therapy and/
or ASCT consolidation in ﬁrst remission; all other frontline treatments
were considered less intensive. Second-line therapy was categorized
as CIT, Bruton’s tyrosine kinase inhibitor (BTKi) therapy for patients
treated with BTKi as a single agent or in combination, and lenalidomide and/or bortezomib treatment of patients treated with 1 or both
agents, including in combination with monoclonal antibodies. Patients
undergoing allogeneic hematopoietic cell transplant (HCT) after
relapse were identiﬁed for purposes of descriptive analysis.

Validation cohort
Adult patients with MCL treated at BC Cancer with frontline bendamustine and rituximab (BR); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); or rituximab, cyclophosphamide,
vincristine, and prednisone (R-CVP) were identiﬁed using the BC Cancer Centre for Lymphoid Cancer clinical and pathology databases,
which have been described.9,30 Frontline therapy was administered
according to institutional practice, with patients treated with
R-CHOP or R-CVP from January 2003 through May 2013 and patients
treated with BR from March 2012 through December 2018. ASCT
consolidation was performed in ﬁt patients aged ,70 years and
responding to frontline CIT. Patients with documented POD were
included in the analysis. As complete data regarding date of initiation
of frontline therapy was available for all patients and a subset of patients
were managed initially with observation, relapse groups were deﬁned
from the start of CIT rather than from date of diagnosis. Patients were
categorized by time to POD as PRF/POD6, POD6-24, or POD.24.

Statistical considerations
OS from the time of ﬁrst POD (OS2) was estimated using the KaplanMeier method, censoring patients who were alive at the time of last
follow-up. Secondary progression-free survival (PFS2) likewise was
estimated beginning at ﬁrst POD by using the Kaplan-Meier method,
censoring patients who were alive and without evidence of progression at last follow-up. OS2 and PFS2 were compared between time
to POD categories using the log-rank test. Univariable and multivariable analyses were performed by using Cox proportional hazard models ﬁt for OS2. Ninety-ﬁve percent conﬁdence intervals (CIs) were
calculated for all estimates. Comparison of baseline characteristics
of the POD groups in the training cohort were compared by using
14 DECEMBER 2021 • VOLUME 5, NUMBER 23

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/5/23/5179/1849644/advancesadv2021004765.pdf by guest on 26 January 2022

over the past 2 decades, coinciding with the development of monoclonal antibodies targeting CD20, intensiﬁcation of initial therapies, and
the more recent targeted oral therapies.1-3 Although median survival
exceeds 10 years in younger patients with MCL who were treated in
the rituximab era, MCL is a highly heterogeneous disease, and a subset
of patients continue to experience poor outcomes, even with modern
therapies, with roughly 15% to 20% of patients progressing within 2
years of frontline treatment.3-9 The MCL international prognostic index
(MIPI) risk score, based on clinical features at the time of diagnosis, is a
well-validated tool for prognostic risk stratiﬁcation of patients with
MCL.10-12 Additional biologic MCL risk factors include increased proliferation rate (high Ki-67), blastoid morphology, loss-of-function mutations within TP53, and genomic instability, as reﬂected by a complex
karyotype (CK), each of which are associated with an adverse prognosis with frontline chemoimmunotherapy (CIT).13-16

Pearson’s x2 test for categorical variables and analysis of variance for
numerical covariates. Comparisons of clinical characteristics between
the primary and validation cohort were performed by using Pearson’s
x2 test. Statistical signiﬁcance was assessed at the P , .05 level, and
statistical analysis was performed using SAS 9.4 (SAS Institute Inc,
Cary, NC) for the training cohort and with SPSS 13.0 (SPSS Inc, Chicago, IL) for the validation cohort.

Results
Training cohort

Baseline characteristics for the 455 patients with relapsed disease
are displayed in Table 1. The median follow-up was 2.6 years (range,
0-15.3) from ﬁrst progression. Frontline treatment was classiﬁed as
intensive in 54% of patients. The median time from date of diagnosis
to start of treatment was 31 days (range, 0-1878). Seventy-one
patients (17%) had a diagnosis to treatment interval greater than 90
days (Table 1). The most common frontline treatments were rituximab,
hyperfractionated cyclophosphamide, vincristine, doxorubicin, and
dexamethasone, alternating with high-dose cytarabine and methotrexate (R-Hyper CVAD) in 117 patients (26%); R-CHOP in 112 patients
(25%); BR in 89 patients (19%); and rituximab with methotrexate,
cyclophosphamide, vincristine, doxorubicin, and prednisone followed
by high-dose cytarabine chemomobilization in 45 patients (10%; supplemental Table 1). A total of 49 patients (11%) were enrolled in a
clinical trial for frontline treatment. One hundred eighty patients
(40%) underwent ASCT consolidation in ﬁrst remission, and
110 patients (24%) received maintenance rituximab, including 34
patients who received maintenance rituximab after ASCT. Secondline treatments were recorded for 377 patients and included
CIT in 145 patients, BTKi in 108 patients, and lenalidomide and/or
bortezomib–containing treatment in 73 patients (supplemental Table
2). In total, 17 patients (4%) underwent ASCT at any time after ﬁrst
progression of disease. One hundred thirty patients (29%) were
enrolled in a therapeutic clinical trial for $1 line of therapy.
Sixty-ﬁve patients (14%) were categorized as PRF/POD6, 153
patients (36%) as POD6-24, and 237 patients (52%) as POD.24.
In comparing patients with relapsed disease according to time of
POD, patients with PRF/POD6 or POD6-24 compared with those
with POD.24 were older on average (median age, 66 for PRF/
POD6, 63 for POD6-24, and 60 for POD.24; P 5 .002), and a
greater proportion had established MCL risk factors, including highrisk MIPI (46% PRF/POD6, 39% POD6-24, and 20% POD.24;
P 5 .002), a Ki67 index .30% (64% PRF/POD6, 60% POD6-24,
and 32% POD.24; P , .001), and CK (14% PRF/POD6, 35%
POD6-24, and 10% POD.24; P 5 .001). In addition, a greater proportion of patients in the POD.24 relapse category had an initial
diagnosis-to-treatment interval .90 days (8% PRF/POD6, 10%
POD6-24, and 24% POD.24; P , .001). A comparison of baseline
characteristics between POD groups is displayed in Table 1.
We ﬁrst sought to determine the association of time to POD with PFS2
and OS2. The median OS from ﬁrst progression (OS2) among relapsed
patients was 1.3 years (95% CI, 0.9-2.4) for patients with PRF/POD6, 3
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As prior reports regarding the prognostic signiﬁcance of early relapse
in MCL have focused on patients who were treated with intensive
frontline approaches, we analyzed outcomes among relapsed patients
categorized by frontline treatment intensity. Among patients receiving
less intensive frontline treatment (ie, R-CHOP or BR without ASCT
consolidation), median OS2 after relapse was 2 years (95% CI,
0.9-4.5) for patients with PRF/POD6, 6.8 years (95% CI, 3.1-9.7)
for patients with POD6-24, and 10.5 years (95% CI, 5.8-NR) for
patients with POD.24 (Figure 1C). Among patients treated with
intensive frontline therapy, median OS2 was 0.9 years (95% CI,
0.4-3) in the PRF/POD6 group, 2 years (95% CI, 1.1-3.4) in the
POD6-24 group, and 9.5 years (95% CI, 4.8-NR) in the POD.24
group (Figure 1D).
To assess the impact of time to POD on survival and the association
with known prognostic risk factors in MCL, univariable analysis was performed to assess the association of time to relapse and baseline patient
and tumor characteristics with OS2 (Table 2). Baseline characteristics
associated with inferior survival from time of relapse included blastoid
histology (hazard ratio [HR], 1.9; 95% CI, 1.3-2.9), stage IV disease
(HR, 2.0; 95% CI, 1.2-3.3), CK (HR, 2.2; 95% CI, 1.1-4.4), presence
of B symptoms (HR, 1.4; 95% CI, 1.0-2.0), and high-risk MIPI score
(HR, 2.5; 95% CI, 1.4-4.3). Early POD was associated with inferior survival from ﬁrst relapse, with HR, 3.8 (95% CI, 2.5-5.8) for PRF/POD6
and HR, 2.1 (95% CI, 1.5-2.9) for POD6-24 in comparison with
POD.24. Receipt of rituximab maintenance was associated with
improved OS2 (HR, 0.6; 95% CI, 0.4-0.9).
We next performed multivariable analysis to determine whether the
association between time to relapse and OS2 was independent of
MIPI risk score at diagnosis and the presence of B symptoms. The
presence of B symptoms was included in the multivariable model,
given that this was determined to be a signiﬁcant prognostic factor
in the univariable analysis and was available for most of the patients.
MIPI risk score was included, as this is a robust and wellestablished prognostic marker for MCL, including in relapsed disease.5,31 Other baseline prognostic factors that were associated
with adverse risk on univariable analysis, such as CK, were not
included in the multivariable model because of the amount of missing
data, and thus the small sample size for this calculation. On multivariable analysis, both high-risk MIPI score (HR, 2.1; 95% CI, 1.2-3.9;
P 5 .011) and PRF/POD6 (HR, 2.7; 95% CI, 1.4-5.2; P 5 .002)
remained independently associated with inferior OS2. In the multivariable model, POD6-24 was not independently associated with inferior
OS2 (HR, 1.3; 95% CI, 0.8-2.4; P 5 .324); however, baseline MIPI
risk score was available for less than half of all patients, possibly limiting power for this calculation (Table 2).

Validation cohort
Having established an association between shorter time to POD
and increased mortality risk in our training cohort, including
patients treated with less intensive therapy, we sought to validate
these ﬁndings in a separate independent cohort. For the validation
cohort, adult patients with relapsed/refractory MCL treated at BC
Cancer after frontline BR, R-CHOP, or R-CVP were included.
OUTCOMES BY TIME TO FIRST POD IN MCL
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In total, 1168 patients with a diagnosis of MCL were identiﬁed: the
median PFS was 4.6 years, with a median follow-up of 3.5 years
(range, 0.3-20.6) from diagnosis. A total of 455 patients (39%) had
documented relapse of disease after frontline treatment and were
therefore included in the subsequent analysis.

years (95% CI 2-6.8) for patients with POD6-24, and 8 years (95% CI,
6.2-not reached [NR]) for patients with POD.24 (Figure 1A). The
median PFS2 was 1 year (95% CI, 0.4-1.3) for patients with PRF/
POD6, 1 year (95% CI, 0.8-1.4) for patients with POD6-24, and 2.3
years (95% CI, 1.8-3.2) for patients with POD.24 (Figure 1B).

Table 1. Comparison of baseline patient characteristics among POD groups
Total*
n 5 455
n (%)

PRF/POD6
n 5 65
n (%)

Median (range)

62 (32-93)

66 (32-86)

Mean

61

63

Variable

POD6-24
n 5 153
n (%)

POD.24
n 5 237
n (%)

P

63 (38-87)

60 (32-93)

.002

63

59

Age at diagnosis

Sex
Female

104 (23)

12 (18)

35 (23)

57 (24)

Male

351 (77)

53 (82)

118 (77)

180 (76)

0-1

346 (94)

52 (93)

112 (90)

182 (96)

$2

24 (6)

4 (7)

12 (10)

.636

ECOG PS

Ann Arbor stage
1-3

62 (14)

7 (11)

12 (8)

43 (19)

378 (86)

57 (89)

135 (92)

186 (81)

Yes

210 (57)

32 (55)

86 (67)

92 (51)

No

157 (43)

26 (45)

42 (33)

89 (49)

Yes

72 (23)

12 (24)

29 (27)

31 (19)

No

247 (77)

39 (76)

80 (73)

128 (81)

Yes

126 (31)

15 (25)

61 (45)

50 (24)

No

276 (69)

45 (75)

75 (55)

156 (76)

Low risk

74 (35)

10 (27)

17 (22)

47 (47)

Intermediate risk

72 (34)

10 (27)

29 (38)

33 (33)

High risk

67 (31)

17 (46)

30 (39)

20 (20)

#30%

93 (50)

13 (36)

32 (40)

48 (68)

.30%

94 (50)

23 (64)

48 (60)

23 (32)

4

.011

Splenomegaly
.016

LN >5 cm
.386

B symptoms
,.001

MIPI risk score
.002

Ki67
,.001

Complex karyotype
Yes

30 (20)

3 (14)

20 (35)

7 (10)

No

121 (80)

18 (86)

37 (65)

66 (90)

.001

Histology
Blastoid

61 (20)

15 (33)

28 (26)

18 (12)

245 (80)

31 (67)

79 (74)

135 (88)

345 (83)

54 (92)

128 (90)

163 (76)

.90

71 (17)

5 (8)

14 (10)

52 (24)

Not recorded

39

6

11

22

Nonblastoid

.001

Diagnosis to treatment interval, d
0-90

,.001

LN, lymph node.
*Total number ,455 in some categories because of missing data.

A total of 245 patients were identiﬁed with a median follow-up of
2.2 years, including 56 patients receiving ﬁrst-line treatment with
BR, 169 patients with R-CHOP, and 20 patients with R-CVP; 52
patients (21%) underwent ASCT consolidation after induction
therapy, and 48% received R-maintenance. In comparison with
the training cohort, a greater proportion of patients in the validation cohort were .65 years of age, had an ECOG performance
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status of .1 and largest nodal mass $5 cm in diameter, and
did not undergo consolidative ASCT (supplemental Table 3). Of
the 245 patients with relapsed disease, 42 (17%) were categorized as PRF/POD6, 104 (42%) as POD6-24, and 99 (40%) as
POD.24 after the start of treatment. A comparison of baseline
characteristics by time-to-relapse category is displayed in supplemental Table 3.
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8 (4)
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Figure 1. Survival and training cohorts. Kaplan-Meier plots of OS from ﬁrst relapse (A), PFS from ﬁrst relapse (B), OS from ﬁrst relapse among patients treated with less
intensive frontline treatment (C), and OS from ﬁrst relapse among patients treated with intensive frontline treatment (D), categorized by duration of ﬁrst remission.

At a median follow-up of 2.2 years, the median OS2 in the validation
cohort was 0.3 years (95% CI, 0.1-0.5) among patients with PRF/
POD6, 0.8 years (95% CI, 0.6-0.9) among those with POD6-24,
and 2.4 years (95% CI, 2.1-2.7) among those with POD.24 (Figure
2A). Among the patients treated with frontline BR, the median OS2
was 0.2 years (95% CI, 0.1-1.4) among those with PRF/POD6, 0.8
years (0.4-1) among those with POD6-24, and not reached among
those with POD.24 (Figure 2B). Among the patients treated with
frontline R-CHOP/R-CVP, median OS2 was 0.3 years (95% CI, 00.7) among those with PRF/POD6, 0.7 years (95% CI, 0.6-0.9)
among those with POD6-24, and 2.4 years (95% CI, 2.1-2.7) among
those with POD.24 (Figure 2C). Finally, among the patients receiving ASCT consolidation, the median OS2 was 0.4 years (0.1-0.7)
among those with POD within 24 months of the start of therapy vs
2.6 years (95% CI, 1.8-3.4) among those with POD.24 (Figure 2D).
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On univariable analysis, shorter duration of ﬁrst remission was associated with inferior OS2 in the validation cohort, with an HR of 2.9 (95%
CI, 2.6-5.8) among patients with PRF/POD6 and an HR of 2 (95% CI,
1.4-2.7) among patients with POD6-24 (supplemental Table 5). On
multivariable analysis incorporating MIPI risk score and time-to-POD
category (n 5 168 patients with available baseline MIPI risk score),
PRF/POD6 and POD6-24 remained independently associated with
inferior OS2 (PRF HR, 3.4; 95% CI, 2-5.7; P , .001; POD6-24
HR, 1.5; 95% CI, 1-2.35; P 5 .05) in the validation cohort (Table 3).

Outcomes by class of second-line therapy after
early POD
Given that patients in the early (PRF/POD6) POD group had the
greatest risk of early mortality, we sought to determine whether class
of second-line treatment was associated with differences in survival
OUTCOMES BY TIME TO FIRST POD IN MCL

5183

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/5/23/5179/1849644/advancesadv2021004765.pdf by guest on 26 January 2022

0.0

0.6

Table 2. Association between risk factors and overall survival from ﬁrst progression
Variable
Age

n

HR (95% CI) by univariable analysis

452

1.02 (1.01-1.04)

P
(HR)
.003

Stage
1-3
4

62

—

378

1.95 (1.17-3.27)

HR (95% CI) by multivariable analysis

P
(HR)

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

1.27 (0.75-2.15)

0.376

—

—

—
.010

Splenomegaly
Yes

210

1.50 (1.07-2.11)

No

157

—

.018

Yes

72

0.98 (0.64-1.50)

No

247

—

Yes

315

1.91 (1.15-3.17)

No

59

—

.30

94

1.24 (0.76-2.03)

#30

93

—

Yes

30

2.21 (1.12-4.36)

No

121

—

Yes

61

1.93 (1.28-2.90)

No

245

—

Yes

232

1.25 (0.92-1.72)

No

198

—

Yes

126

1.41 (1.02-1.96)

No

276

—

High risk

67

2.45 (1.38-4.32)

.002

2.14 (1.19-3.85)

0.011

Intermediate risk

72

1.24 (0.67-2.30)

.485

1.24 (0.66-2.33)

0.499

Low risk

74

—

—

—

—

—

.928
—

BM involvement
.012
—

Ki67%
.384
—

CK
.022
—

Blastoid histology
.002
—

Intensive treatment
.157
—

B symptoms
.037
—

MIPI risk score

Time to POD
65

3.76 (2.46-5.75)

,.001

2.71 (1.42-5.17)

0.002

POD6-24

153

2.12 (1.53-2.93)

,.001

1.33 (0.75-2.35)

0.324

POD.24

237

—

—

—

—

PRF/POD6

BM, bone marrow; LN, lymph node.

outcomes in this highest risk group of our training cohort. Of 65
patients categorized as PRF/POD6, second-line treatment was
recorded for 53 patients. Twenty-two patients received CIT; 21
received BTKi treatment, either as a single agent (14 patients) or in
combination with CIT or other novel agents (7 patients); 8 received
bortezomib and/or lenalidomide, with or without anti-CD20 monoclonal antibodies; and 2 received supportive care only. Median PFS2 was
0.3 years (95% CI, 0.1-0.6) for patients treated with lenalidomide and/
or bortezomib, 0.5 years (95% CI, 0.2-2.3) for those treated with CIT,
and 1.2 years (95% CI, 0.5-2.3) for those treated with BTKi (P 5 .04;
Figure 3A). Among patients treated with BTKi, the PFS2 was not
superior in those who had combination therapy (median PFS2, 1.4
5184
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years for single-agent BTKi and 0.7 years for patients treated with
BTKi-based combination therapy). The median OS2 from ﬁrst relapse
was 1.9 years (95% CI, 0.1-2) in patients treated with lenalidomide
and/or bortezomib, 1.1 years (95% CI, 0.5-NR) in patients treated
with CIT, and 2.4 years (95% CI, 0.7-4.5) in patients treated with
BTKi (P 5 .55; Figure 3B).

Outcomes after allogeneic HCT
A total of 54 patients underwent allogeneic HCT for relapsed or
refractory disease, including 12 with PRF/POD6, 19 with POD624, and 23 with POD.24. The median time from ﬁrst relapse to
14 DECEMBER 2021 • VOLUME 5, NUMBER 23

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/5/23/5179/1849644/advancesadv2021004765.pdf by guest on 26 January 2022

LN >5 cm

1.0

Logrank p < .001

Survival probability

0.8

0.6

Refractory_
Group
POD>24
POD6–24
PRF/POD6
POD>24censored
POD6-24censored

0.4

B
1.0

Logrank p < .001

0.8

Survival probability

A

0.6

Refractory_
Group
POD>24
POD6–24
PRF/POD6
POD>24censored
POD6-24censored

0.4

0.2

0.0

0.0
0

0 1 2 3 4 5 6 7 8 9 10 11 12

1

2

3

4

5

Overall survival (years from 1st progression)

Overall survival (years from 1st progression)

D
1.0

Logrank p < .001

Survival probability

0.8
0.6

Refractory_
Group
POD>24
POD6–24
PRF/POD6
POD>24censored
POD6-24censored

0.4

1.0

Logrank p < .001

0.8

Survival probability

C

0.6

Refractory_
Group
POD>24
POD6–24
POD>24censored
POD6-24censored

0.4

0.2

0.2

0.0

0.0
0 1 2 3 4 5 6 7 8 9 10 11 12

0 1 2 3 4 5 6 7 8 9 10 11 12

Overall survival (years from 1st progression)

Overall survival (years from 1st progression)

Figure 2. Survival of the validation cohort. Kaplan-Meier plots of OS from ﬁrst progression, all patients (A); OS from ﬁrst progression among patients treated with BR only
(B); OS from ﬁrst progression in patients treated with R-CHOP or R-CVP only (C); and OS from ﬁrst progression among patients who underwent ASCT consolidation in ﬁrst
remission only (D); all categorized by duration of ﬁrst remission. In panel D, n 5 42 treated with R-CHOP/R-CVP; n 5 10 treated with BR.

allogeneic HCT was 0.7 years, and the median follow-up after allogeneic HCT was 2.5 years. The median OS2 among patients who
underwent allogeneic HCT was 7.5 years, including a median OS2
of 3.0 years among patients with ﬁrst relapse before 24 months
(PRF/POD6 and POD6-24) and 9.5 years among those with ﬁrst
relapse after 24 months. Among patients with PRF/POD6, median
OS2 was 2.0 years in those who underwent allogeneic HCT and
1.1 years in those who did not undergo transplant.

Discussion
To our knowledge, this represents the largest report to date that
describes the prognostic signiﬁcance of time to ﬁrst relapse in
patients with MCL. Consistent with the prior literature,24,25
POD,24 months of intensive therapy was associated with increased
risk for early mortality in both the training and validation cohorts, identifying a high-risk population that may be preferentially selected for
investigation of novel therapies in the second-line setting. In addition,
14 DECEMBER 2021 • VOLUME 5, NUMBER 23

we observed a strong association between time to POD and OS2
among patients treated with less intensive frontline treatment. This
association was replicated in the validation cohort, including in the
subgroup of patients treated with BR, which is currently a widely
used frontline regimen. Among patients with early relapse after less
intensive frontline treatment, outcomes were particularly poor in
patients classiﬁed as PRF/POD6. The inferior OS2 among those
patients in comparison with patients with later relapse (POD6-24) is
consistent with observations in patients with follicular lymphoma
treated in the GALLIUM study and suggests that duration of ﬁrst
remission among patients with early relapse may be a continuous variable providing prognostic information beyond a binary 24-month
duration of the ﬁrst remission cutoff.29
We observed a consistent association between early POD and
increased mortality in patients with MCL across all analyzed treatment
subgroups in 2 large, independent cohorts. We likewise conﬁrmed
that the association between PRF/POD6 and inferior secondary survival had prognostic signiﬁcance, independent of baseline MIPI risk
OUTCOMES BY TIME TO FIRST POD IN MCL
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0.2

Table 3. Association between risk factors and OS from ﬁrst
progression in validation cohort, by multivariable analysis
HR (95% CI)

P

High

3.58 (2.24-5.71)

,.001

Intermediate

1.49 (0.94-2.36)

.090

Variable
MIPI risk score

—

PRF/POD6

3.39 (2.04-5.65)

,.001

POD6-24

1.54 (1.01-2.35)

.046

POD.24

—

Time to POD

—

n 5 168 patients.

score in both patient cohorts. This ﬁnding suggests that duration of
ﬁrst remission is a relevant prognostic factor that should be included
among the baseline clinical characteristics describing clinical trial participants enrolled in second-line MCL treatment studies.
The estimated OS2 in our training cohort signiﬁcantly exceeded the
median follow-up among patients with relapse .24 months from diagnosis, thus limiting the reliability of these estimates. Patients in our
training cohort were primarily treated at tertiary referral centers, and
the relatively low proportion of patients with relapsed disease may
be explained in part by loss to follow-up among a subset of patients
ultimately treated at local community centers at ﬁrst progression. In
addition, patients who are treated at an academic center may be ﬁtter
and therefore able to travel for evaluation and treatment compared
with other patients. Likewise, among the patients with relapsed disease included in our analysis, censoring of patients lost to follow-up
who may have received treatment at other centers for relapsed disease may result in overestimation of secondary OS. Although the

A

Progression free survival from first relapse
1.0

Although duration of ﬁrst remission has the inherent limitation that it is
known only at the time of progression and by deﬁnition cannot inform
choice of frontline treatment, the prognostic signiﬁcance of a short
duration of ﬁrst remission is useful, both in clinical practice for counseling of patients and in the design of prospective trials of second-line
therapies. Ongoing study is needed to further deﬁne biologic MCL
risk factors, including genetic and epigenetic alterations associated
with early POD, to provide better prognostication at diagnosis and
inform selection of frontline treatment. A growing body of evidence
has established TP53 mutations as one important biologic risk factor
in MCL predictive of poor response to CIT and early mortality,15,32-34
and the lack of data regarding TP53 mutational status is a limitation of

B
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Figure 3. Comparative survival for patients with PRE/POD6 by second-line treatment. Figure PFS (A) and OS (B) from ﬁrst progression of disease by salvage treatment
category. BTKi, either as a single agent or in combination with other treatments; Lena, treatment with lenalidomide and/or bortezomib, either as a single agent or in combination
with other treatments.
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—

Low

data from our validation cohort support the prognostic signiﬁcance
of duration of ﬁrst remission in MCL, OS2 was notably shorter in
the validation cohort, particularly among patients in the POD.24
group. This discrepancy may be due in part to differences in baseline
characteristics between patient populations, including a younger
median age and higher proportion of patients with performance status
of 0 or 1 in the training cohort relative to the validation cohort. There
was a greater use of intensive therapies in the training cohort, including cytarabine-containing regimens and ASCT, possibly reﬂecting
referral of ﬁtter patients to academic centers in the United States
cohort compared with the broad, province-wide population base comprising the validation cohort. Second and subsequent lines of therapy
were different between both populations, with a greater number of
patients in the training cohort receiving novel agents and undergoing
allogeneic HCT. Finally, as previously stated, censoring of patients lost
to follow-up who received treatment at other centers may lead to overestimation of OS2 in the training cohort but was not likely to occur in
the validation cohort, which serves as the sole provider of oncology
care for the entire province of BC where up-to-date death data are
generally reliable.

the current study. In addition, the impact of TP53 mutations on
response to salvage therapy and/or novel agents is not well
described.

Our study, which includes a large patient population treated in the
modern era, has important limitations, some of which are inherent to
the retrospective nature of the study in a rare disease with no standard
approach to treatment. Limitations include the variability in ﬁrst- and
second-line therapies, incomplete data for prognostic variables of
interest, including MIPI risk score and Ki67 proliferation index, and
lack of molecular data, including speciﬁcally TP53 mutational status.
Strengths of our study include the large patient cohort, over twice
the size of the largest prior report25 analyzing the prognostic signiﬁcance of time to relapse in MCL, inclusion of patients receiving less
intensive frontline treatment, which make up a large share of patients
treated in clinical practice, and validation of these ﬁndings in a large,
independent, population-based cohort.
In summary, progression of MCL within 24 months of the start of treatment is associated with inferior OS2, and patients with primary refractory disease are at highest risk of early death. Further study is
warranted to better characterize the biology of this high-risk patient
population. These ﬁndings have implications for clinical practice and
to inform the selection of high-risk patients for future prospective therapeutic studies of relapsed MCL.
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Among patients with primary refractory disease, we observed a longer
duration of PFS2 (1.2 years) than the duration of ﬁrst remission among
patients treated with BTKi as the second-line therapy. Longer secondary PFS than duration of ﬁrst remission was similarly observed in
patients with MCL with early relapse treated with second-line ibrutinib
in pooled long-term follow-up of prospective studies,35 and a recent
multicenter cohort study reported greater PFS2 among younger
patients with early relapse of MCL treated with BTKi in comparison
with CIT, with an estimated median PFS2 of 10 months.36 However,
the responses to BTKi second line were not durable, and no difference in OS2 was observed compared with other classes of
second-line therapy.
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